Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 8/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 4/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31521573 | 0.86 | CA2 (0.40) | CA2ALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL23923984 | 0.83 | CA2 (0.39) | CA2ALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL31521547 | 0.82 | CA2 (0.42) | CA2ALDH1A1TDP1TSHRMAPK1 | |
| SCHEMBL23923859 | 0.82 | CA2 (0.42) | CA2ALDH1A1TDP1TSHRMAPK1 | |
| SCHEMBL31521517 | 0.82 | CA2 (0.40) | CA2ALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL23923680 | 0.78 | ACE2 (0.38) | CA2TDP1TSHRMAPK1CA1 | |
| SCHEMBL31521549 | 0.76 | ALDH1A1 (0.52) | CA2ALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL31521545 | 0.76 | ALDH1A1 (0.52) | CA2ALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL31521540 | 0.76 | CA2 (0.41) | CA2ALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL31521575 | 0.75 | ALDH1A1 (0.50) | CA2ALDH1A1TDP1CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11174205-B2 | C20 2-substituted alpha olefins produced by dimerization of branched C10 olefins | CHEVRON PHILLIPS CHEMICAL COMPANY, LP (US) | 2021-11-16 | — | — | US | claimed |
| US-20210323892-A1 | C20 2-Substituted Alpha Olefins Produced By Dimerization Of Branched C10 Olefins | CHEVRON PHILLIPS CHEMICAL COMPANY LP | 2021-10-21 | — | — | US | claimed |
| WO-2025264609-A1 | C20 TRISUBSTITUTED OLEFINS PRODUCED BY ACIDIC CATALYZED REACTION OF C20 2-SUBSTITUTED ALPHA OLEFINS | CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) | 2025-12-26 | — | — | WO | disclosed |
| US-20250382242-A1 | C20 TRISUBSTITUTED OLEFINS PRODUCED BY ACIDIC CATALYZED REACTION OF C20 2-SUBSTITUTED ALPHA OLEFINS | CHEVRON PHILLIPS CHEMICAL CO LP (US) | 2025-12-18 | — | — | US | disclosed |
| US-11174205-B2 | C20 2-substituted alpha olefins produced by dimerization of branched C10 olefins | CHEVRON PHILLIPS CHEMICAL COMPANY, LP (US) | 2021-11-16 | — | — | US | disclosed |
| US-20210323892-A1 | C20 2-Substituted Alpha Olefins Produced By Dimerization Of Branched C10 Olefins | CHEVRON PHILLIPS CHEMICAL COMPANY LP | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382242-A1 | C20 TRISUBSTITUTED OLEFINS PRODUCED BY ACIDIC CATALYZED REACTION OF C20 2-SUBSTITUTED ALPHA OLEFINS | COASY, MOGAT2, HSD17B12 | CA2 1500/4885ALDH1A1 980/4885TDP1 4288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.